Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 5,931 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mouth Disease Clear all
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration

NCT00587834
View directory record Official record
Conditions
Gingival Recession
Interventions
Gintuit, Autologous palatal tissue
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
4
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Nov 15, 2026, 5:14 AM EST
Terminated Phase 2 Interventional

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

NCT00745316
View directory record Official record
Conditions
Renal Insufficiency, Heart Failure
Interventions
Tonapofylline, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Nov 15, 2026, 5:14 AM EST
Recruiting No phase listed Observational

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

NCT05656365
View directory record Official record
Conditions
Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa), Obstructive Sleep Apnea, Tonsillitis, Tonsil Disorder, Sleep Disordered Breathing
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 99 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2026 · Synced Nov 15, 2026, 5:14 AM EST
Completed Not applicable Interventional

Vibrent Smartphone Mobile Application

NCT02421536
View directory record Official record
Conditions
Mucositis
Interventions
Vibrogent Smartphone Application
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 2 Interventional

The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease

NCT00250198
View directory record Official record
Conditions
Crohn's Disease
Interventions
STA-5326
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 2 Interventional

Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to Allopurinol

NCT01265264
View directory record Official record
Conditions
Gout, Hyperuricemia, Arthritis, Joint Disease
Interventions
ulodesine, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years to 69 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
54
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 2 Interventional Results available

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cyclophosphamide and Sirolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 3 Interventional

Estrogen Treatment (Oral vs. Patches) in Turner Syndrome

NCT00140998
View directory record Official record
Conditions
Turner Syndrome, Hypogonadism, Premature Ovarian Failure
Interventions
17 beta estradiol
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
10 Years to 16 Years · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 2 Interventional

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

NCT05600114
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Cannabidiol oral solution, Placebo
Drug
Lead sponsor
EmpowerPharm Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
17
States / cities
Encino, California • Lemon Grove, California • Los Alamitos, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 1 Interventional

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

NCT00138216
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
irinotecan hydrochloride, temozolomide, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
16
States / cities
Birmingham, Alabama • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Nov 15, 2026, 5:14 AM EST
Recruiting Not applicable Interventional

Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.

NCT07187388
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS), Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
Transcutaneous Electrical Nerve Stimulation to reduce facial pain and improve jaw range of motion in ALS and PLS
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Davie, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Nov 15, 2026, 5:14 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Influence of SRP With MM on the Composition and Functional Characteristics of Subgingival Microbiome Communities

NCT05422742
View directory record Official record
Conditions
Periodontitis
Interventions
SRP + MM, Scaling and Root Planing (SRP)
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Nov 15, 2026, 5:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age

NCT06582056
View directory record Official record
Conditions
Periodontal Disease
Interventions
Investigational Procedure
Procedure
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
30 Years to 70 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
Iowa City, Iowa • Somerville, Massachusetts • Stony Brook, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 1 Interventional

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-930
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Aurora, Colorado • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Nov 15, 2026, 5:14 AM EST
Terminated Phase 2 Interventional Results available

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770
View directory record Official record
Conditions
Sjögren's Syndrome, Xerostomia
Interventions
Dexamethasone Parotid Irrigation, Placebo Parotid Irrigation
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Nov 15, 2026, 5:14 AM EST
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Nov 15, 2026, 5:14 AM EST
Terminated Early Phase 1 Interventional

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596
View directory record Official record
Conditions
Retinal Detachment, Rhegmatogenous Retinal Detachment
Interventions
Lamivudine 300 MG, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 2 Interventional Results available

Impact of Periodontal Therapy on Patients With Diabetes

NCT04830969
View directory record Official record
Conditions
Diabetes Mellitus, Type II, Periodontitis
Interventions
Chlorhexidine gluconate oral rinse, Scaling & Root Planing, Soft Picks
Drug · Procedure · Device
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
25 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Nov 15, 2026, 5:14 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin

NCT01107431
View directory record Official record
Conditions
Pre-diabetes
Interventions
L-Arabinose and Chromium, Sucrose without dietary Supplement
Dietary Supplement
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Nov 15, 2026, 5:14 AM EST
Recruiting Early Phase 1 Interventional

Window of Opportunity Study of DSP-0390 in Gliomas

NCT06636162
View directory record Official record
Conditions
Glioma, Malignant, IDH Mutation
Interventions
DSP-0390
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Nov 15, 2026, 5:14 AM EST
Terminated Phase 3 Interventional Results available

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02120027
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
73
States / cities
Chandler, Arizona • Glendale, Arizona • Mesa, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Nov 15, 2026, 5:14 AM EST
Completed Phase 1Phase 2 Interventional

Gimatecan in Treating Patients With Recurrent or Progressive Primary Malignant Glioma

NCT00087061
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
gimatecan
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Nov 15, 2026, 5:14 AM EST
Recruiting Phase 1 Interventional

A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Severe Renal Impairment or End Stage Renal Disease

NCT07559396
View directory record Official record
Conditions
Renal Impairment
Interventions
INCB123667
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Nov 15, 2026, 5:14 AM EST